ＲＡＤ５１阻害薬としての求電子剤および求電子剤プロドラッグ

• Format: Patent
• Language: Japanese
• Published: 18.01.2022
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

がんを有するか、がんを有する疑いがあるか、またはがんを発症するリスクがある対象に、（ａ）（ｉ）ニトロアルケン脂肪酸、（ａ）（ｉｉ）電子吸引性基、脱離基、および電子吸引性基と脱離基との間に配置された炭素間二重結合を有する不飽和脂肪酸、（ａ）（ｉｉｉ）チオール化ニトロ脂肪酸、または（ａ）（ｉｖ）電子吸引性基を含有するジカルボン酸化合物から選択される、治療有効量の少なくとも１種の化合物（ａ）と、治療有効量の少なくとも１種の抗新生物剤（ｂ）とを同時投与することを含む方法であって、がんが、ＤＮＡ修復遺伝子の欠陥の遺伝的病因に関するがん、高頻度の自然ゲノム不安定性を有するがん、ＤＮＡ損傷剤に良好に応答するがん、またはＤＮＡ損傷剤と免疫療法との組合せに良好に応答するがんである、方法。 A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer:a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, (a)(ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (a)(iii) a thiolated nitro fatty acid, or (a)(iv) a dicarboxylic acid compound containing an electron withdrawing group; anda therapeutically effective amount of at least one anti-neoplastic agent (b),wherein the cancer is a cancer with hereditary etiology of defects in DNA repair genes, a cancer with a high rate of spontaneous genomic instability, a cancer that responds well to DNA damaging agent(s), or a cancer that responds well to a combination of DNA damaging agent(s) with immunotherapy.